Inspira Technologies

Executive Summary

Inspira Technologies is a preclinical Israeli med-tech company developing a novel acute respiratory support system, the INSPIRA™ ART500, designed to oxygenate blood without intubation. The system integrates the HYLA™ adaptive blood monitoring sensor and the VORTX™ dual-lumen cannula to rapidly raise oxygen saturation in ICU patients who would otherwise require mechanical ventilation. By offering a less invasive alternative, the technology has the potential to reduce complications associated with intubation and shorten ICU stays. Currently in preclinical development, the company is poised to advance toward first-in-human studies. Given the large unmet need for non-invasive respiratory support in critical care, Inspira's platform could address a significant market opportunity. However, the early stage and lack of clinical data present substantial risk.

Upcoming Catalysts (preview)

• Q4 2026First-in-human study initiation40% success
• Q2 2026FDA IDE submission and clearance for clinical trial50% success
• Q3 2026Strategic partnership with a respiratory device company for distribution or co-development35% success